Immunization with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: effect of a booster dose on antibody levels in humans
- PMID: 2454893
- PMCID: PMC259485
- DOI: 10.1128/iai.56.7.1829-1830.1988
Immunization with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: effect of a booster dose on antibody levels in humans
Abstract
Healthy adult volunteers were vaccinated on day 0 and 28 and at 15 months with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine. Immunization resulted in mild, transient local reactions in less than 20% of the subjects. Maximal immunoglobulin G (IgG) antibody titers to both toxin A and lipopolysaccharide (LPS) as determined by enzyme-linked immunosorbent assay were seen at day 42, at which time 50% of the vaccinees showed a fourfold or greater rise in toxin A-neutralizing titers. By 15 months postvaccination, both antitoxin A and anti-LPS IgG antibodies had markedly declined. A booster dose of vaccine administered at 15 months evoked a vigorous anti-toxin A IgG antibody response with 100% of the volunteers showing a fourfold or greater rise in neutralizing antibody titer compared with preimmunization levels. In contrast, there was no significant elevation of anti-LPS IgG antibody levels. At 24 months postimmunization, only anti-toxin A antibody levels were significantly higher than preimmunization levels.
Similar articles
-
Characterization of the human immune response to a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.J Lab Clin Med. 1988 Jun;111(6):701-7. J Lab Clin Med. 1988. PMID: 3131471
-
Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.J Clin Invest. 1987 Jul;80(1):51-6. doi: 10.1172/JCI113062. J Clin Invest. 1987. PMID: 3110215 Free PMC article.
-
Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine.Infect Immun. 1986 Apr;52(1):161-5. doi: 10.1128/iai.52.1.161-165.1986. Infect Immun. 1986. PMID: 3082756 Free PMC article.
-
Use of Pseudomonas aeruginosa toxin A in the construction of conjugate vaccines and immunotoxins.Rev Infect Dis. 1987 Sep-Oct;9 Suppl 5:S644-9. doi: 10.1093/clinids/9.supplement_5.s644. Rev Infect Dis. 1987. PMID: 3120274 Review.
-
Pseudomonas aeruginosa antigens as potential vaccines.FEMS Microbiol Rev. 1997 Nov;21(3):243-77. doi: 10.1111/j.1574-6976.1997.tb00353.x. FEMS Microbiol Rev. 1997. PMID: 9451816 Review.
Cited by
-
Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A.Infect Immun. 1993 Mar;61(3):1023-32. doi: 10.1128/iai.61.3.1023-1032.1993. Infect Immun. 1993. PMID: 8432585 Free PMC article.
-
Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers.Infect Immun. 1996 Oct;64(10):4074-7. doi: 10.1128/iai.64.10.4074-4077.1996. Infect Immun. 1996. PMID: 8926071 Free PMC article. Clinical Trial.
-
Comparative immunogenicity of conjugates composed of Escherichia coli O111 O-specific polysaccharide, prepared by treatment with acetic acid or hydrazine, bound to tetanus toxoid by two synthetic schemes.Infect Immun. 1995 Aug;63(8):2805-10. doi: 10.1128/iai.63.8.2805-2810.1995. Infect Immun. 1995. PMID: 7542631 Free PMC article.
-
Pseudomonas aeruginosa Vaccine Development: Lessons, Challenges, and Future Innovations.Int J Mol Sci. 2025 Feb 25;26(5):2012. doi: 10.3390/ijms26052012. Int J Mol Sci. 2025. PMID: 40076637 Free PMC article. Review.
-
Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines.Infect Immun. 2001 Nov;69(11):6696-701. doi: 10.1128/IAI.69.11.6696-6701.2001. Infect Immun. 2001. PMID: 11598040 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources